Font:
AS

ASTRAZEN / NSE / Biotechnology & Drugs

AstraZeneca Pharma India Ltd

INR 8,600371.50 (1.20%) 1D
Last updated: 2026-06-15T12:27:14.914591+00:00
Price Chart

1Y Price Trend

Open9,960
High10,691
Low7,551.5
Close8,249.5
Volume3,066
Change-1,710.5
Change %-17.17%

Key Information

Ticker SymbolASTRAZEN
Current Price8,600
52-Week High10,653.05
52-Week Low7,630
Market Cap21,556.52
Volume3,066
ISININE203A01020
Day High8,299
Day Low8,213
Open8,299

Recommendations

Target High10,653.05

Target Low7,630

Target Mean0

Target Median0

Risk Metrics

Overall RiskModerate risk

Board Risk24.84

Key Analysis

Overall score, performance score, return rating, defensive, aggressive, and balanced views.

Download app

Projection Analytics

Best-case, base-case, worst-case, and dynamic AI projection views.

Download app
News

Latest stock news

AstraZeneca Pharma India closes trading window until Q1FY27 results - scanx.trade4 days ago
Market news

AstraZeneca Pharma India closes trading window until Q1FY27 results scanx.trade

AstraZeneca Pharma India Accepts Resignations of Two Senior Executives - scanx.trade7 days ago
Market news

AstraZeneca Pharma India Accepts Resignations of Two Senior Executives scanx.trade

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer - IndiaMedToday7 days ago
Market news

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer IndiaMedToday

AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab - Indian Pharma Post8 days ago
Market news

AstraZeneca gets CDSCO nod for Trastuzumab Deruxtecan plus Pertuzumab Indian Pharma Post

AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment - Moomoo8 days ago
Market news

AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment Moomoo

AstraZeneca receives CDSCO approval for Trastuzumab Deruxtecan in combination with Pertuzumab for breast cancer treatment - BioSpectrum India8 days ago
Market news

AstraZeneca receives CDSCO approval for Trastuzumab Deruxtecan in combination with Pertuzumab for breast cancer treatment BioSpectrum India

AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu - CNBC TV188 days ago
Market news

AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu CNBC TV18

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer - The Economic Times8 days ago
Market news

AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer The Economic Times

FAQ

Stock FAQs

What is the NSE symbol for AstraZeneca Pharma India Ltd?

AstraZeneca Pharma India Ltd trades on NSE with the symbol ASTRAZEN. ShareKeyX uses the stock symbol in the public URL and keeps ISIN only for internal data matching and structured data.

Where can I track AstraZeneca Pharma India Ltd share price and chart?

You can track AstraZeneca Pharma India Ltd share price, OHLC chart, key information, ratios, financials, company information and news on this ShareKeyX market page.

Does ShareKeyX show financial data for AstraZeneca Pharma India Ltd?

Yes. ShareKeyX displays available financial statements for AstraZeneca Pharma India Ltd using the current Supabase company financial payload. Statement values are shown in INR crore.

Does ShareKeyX show historical OHLC data for AstraZeneca Pharma India Ltd?

Yes. ShareKeyX displays available historical OHLC candles for AstraZeneca Pharma India Ltd across supported chart ranges such as 7D, 1M, 3M, 6M and 1Y.

What sector or industry does AstraZeneca Pharma India Ltd belong to?

AstraZeneca Pharma India Ltd is classified under Biotechnology & Drugs in the available company data.

Does ShareKeyX show news for AstraZeneca Pharma India Ltd?

Yes. ShareKeyX shows the latest available stock news for AstraZeneca Pharma India Ltd from the connected stock news source.